Section Arrow
Quote
NBIX.NASDAQ
- Neurocrine Biosciences
Quotes are at least 15-min delayed:2026/03/03 18:43 EST
After Hours
Last
 128.05
-3.09 (-2.36%)
Bid
128.05
Ask
135
High 131.14 
Low 128.05 
Volume 16.04K 
Regular Hours (Closed)
Last
 131.14
-1.24 (-0.94%)
Day High 
132.415 
Prev. Close
132.38 
1-M High
142.82 
Volume 
595 
Bid
128.05
Ask
135
Day Low
128 
Open
131.99 
1-M Low
122.1375 
Market Cap 
13.29B 
Currency 美元 
P/E 28.35 
%Yield -- 
10-SMA 130.06 
20-SMA 132.81 
50-SMA 136.21 
52-W High 160.18 
52-W Low 84.23 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
4.67/7.70
Enterprise Value
13.70B
Balance Sheet
Book Value Per Share
32.41
Cash Flow
Cash Flow Yield
0.06
Income Statement
Total Revenue
2.86B
Operating Revenue Per Share
17.77
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
HIMSHims & Hers Health15.82-0.66-4.00%32.25PE
After Hours 15.81 -0.01 -0.06%
VTRSViatris14.9-0.8-5.10%-- 
After Hours 14.77 -0.13 -0.87%
TEVATeva Pharmaceutical Industries Limited32.28-1.49-4.41%27.93PE
After Hours 32.29 +0.01 +0.03%
ESPREsperion Therapeutics2.89-0.385-11.76%-- 
After Hours 2.93 +0.04 +1.38%
BHCBausch Health Companies5.73-0.22-3.70%14.17PE
After Hours 5.79 +0.06 +1.05%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.